Assertio, Garda mutually agree to extend tender offer deadline

Assertio (ASRT) Holdings announced that it has reached a mutual agreement with Garda Therapeutics, Inc. to extend the deadline to commence the previously announced tender offer to acquire all outstanding shares of Assertio to May 4, 2026. As previously announced on April 8, 2026, Assertio has entered into a definitive agreement to be acquired by Garda for $18.00 per share in cash, or a total cash consideration of $125.1 million, plus a contingent value right. The Garda Agreement includes a 20-day “window-shop” period. Under the terms of the window-shop provision, Assertio is free to engage with other parties who may provide superior value to shareholders. In the event the Board terminates the Garda Agreement in favor of a superior bid during the window-shop period, a reduced breakup fee would apply.